Nasodine

Firebrick Pharma is an Australian pharmaceutical company primarily focused on the development and commercialization of Nasodine, a proprietary povidone-iodine nasal spray. Nasodine is designed as a broad-spectrum antimicrobial treatment to target the nasal passages, which are the primary site of infection for the common cold and other respiratory viruses. The company has conducted multiple clinical trials, including Phase 3 studies, to demonstrate Nasodine's efficacy in reducing the severity and duration of the common cold. Beyond the common cold, Firebrick Pharma is exploring the product's utility in reducing viral load for COVID-19 and other respiratory pathogens. The company is headquartered in Melbourne and is listed on the Australian Securities Exchange (ASX).